DRY POWDER FOR INHALATION PREPARATION, INCLUDING SALMETEROL XINAOFAT, FLUTICASONE PROPIONATE AND THIOTROPY BROMIDE, AND ALSO THE METHOD FOR PRODUCING IT
1. A dry powder for an inhalation preparation, including salmeterol xinafoate, fluticasone propionate, tiotropium bromide, and a carrier having an average particle size in the range of 30 to 120 microns. 2. Dry powder for an inhalation preparation according to claim 1, where the average particle size is in the range from 55 to 65 microns. A dry powder for an inhalation preparation according to claim 1, wherein the carrier is selected from the group consisting of monosaccharides, disaccharides, polysaccharides, polyalcohols and their hydrates. 4. Dry powder for an inhalation preparation according to claim 3, wherein the carrier is lactose monohydrate. The dry powder for the inhalation preparation according to claim 1, wherein the dry powder for the inhalation preparation is used to prevent or treat respiratory diseases. Inhalation preparation, including dry powder according to p. 1.7. The inhalation preparation according to claim 6, wherein the amount of carrier used is in the range from 15 mg to 25 mg per dosage unit of the drug. The inhalation preparation according to claim 6, wherein salmeterol xinafoate, fluticasone propionate and tiotropium bromide are used in amounts of 25 to 100 μg, 25 to 500 μg, and 5 to 50 μg per unit dosage, respectively. A method for preparing a dry powder for an inhalation preparation according to claim 1, which comprises the steps of: (1) applying from 5 to 20% by weight of the carrier based on the total amount of carrier on the inner walls of the mixer； (2) grinding salmeterol xinafoate, fluticasone propionate and tiotropium bromide with 5-20% by weight of the carrier based on the total amount of carrier； and (3) mixing and grinding powdered ingredients into a powder and leaving the carrier in a mixer prepared in Stage (1) with a force that does not lead to a significant change in particle size. 10.1. Сухой порошок для ингаляционного препарата, включающий сальметерола ксинафоат, флутиказона пропионат, тиотропия бромид, и носитель, имеющ
